Reliable assessment of the effects of treatment on mortality and major morbidity, I: Clinical trials

Lancet

Volumn 357, Issue 9253, 2001, Pages 373-380

  Collins, Rory ^a   MacMahon, Stephen ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAPTOPRIL; CLOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM; NITRIC ACID DERIVATIVE; OXYTOCIN; POLIOMYELITIS VACCINE; STREPTOKINASE; TAMOXIFEN;

AMNIOTOMY; ANALYTICAL ERROR; BREAST CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DATA ANALYSIS; FIBRINOLYTIC THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PATIENT SELECTION; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZATION; RELIABILITY; REPRODUCIBILITY; REVIEW; STATISTICAL ANALYSIS; STROKE;

EID: 0035798948     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03651-5     Document Type: Review

References (74)

1. Reliable assessment of the effects of treatment on mortality and major morbidity, II: Observational studies
2. Large-scale randomized evidence: Trials and overviews
3. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials
4. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
5. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: Meta-analyses of the randomised evidence
6. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials
7. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews
8. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
9. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
10. The role of randomization in clinical trials
11. The unpredictability paradox: Review of empirical comparisons of randomised and non-randomised clinical trials
12. Amniotomy or oxytocin for induction of labour: Reanalysis of a randomized controlled trial
13. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
14. Failure of randomisation by "sealed" envelope
15. A comparison of observational studies and randomized, controlled trials
16. Randomized, controlled trials, observational studies, and the hierarchy of research designs
17. An evaluation of the 1954 poliomyelitis vaccine trials: Summary report
18. Randomized trials or observational tribulations?
19. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction
20. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project
21. Adjusting for non-compliance and contamination in randomized clinical trials
22. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
23. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
24. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
25. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
26. Final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drugs (FR Doc 98-28519)
27. Discussion sections in reports of controlled trials published in general medical journals: Islands in search of continents?
28. Why sources of heterogeneity in meta-analysis should be investigated
29. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction
30. Is aspirin safe for patients with heart failure?
31. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
32. The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer
33. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
34. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials
35. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease
36. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women
37. Antiplatelet agents for preventing and treating pre-eclampsia
38. Effects of vesnarinone on morbidity and mortality in patients with heart failure
39. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
40. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: A meta-analysis of randomized controlled trials
41. Trial of calcium to prevent preeclampsia
42. Effects of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomised trials
43. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
44. Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomised trials
45. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
46. Low-molecular-weight heparin for the treatment of acute ischemic stroke
47. Anticoagulants for acute ischaemic stroke
48. The effects of nimodipine on the clinical course of patients with acute ischemic stroke
49. Calcium antagonists for acute ischemic stroke
50. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)
51. Dietary supplementation with n-3 polyunsaturated fatty acids, after myocardial infarction: Results of the GISSI-Prevenzione trial
52. Vitamin E supplementation and cardiovascular events in high-risk patients
53. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: Results of an international randomized trial
54. The extracranial-intracranial bypass study: A report of the committee appointed by the American Association of Neurological Surgeons to examine the study
55. Are the results of the extracranial-intracranial bypass trial generalizable?
56. How important is publication bias? A synthesis of available data
57. Estimation issues in clinical trials and overviews
58. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials
59. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years
60. Thrombolytic therapy in older patients
61. Thrombolytic therapy in the elderly
62. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
63. Prediction of benefit from carotid endarterectomy in individual patients: A risk-modelling study
64. Can overall results of clinical trials be applied to all patients?
65. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 Randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
66. Variation in use of adjuvant tamoxifen
67. Tamoxifen for early breast cancer: An overview of the randomised trials
68. An introduction to bayesian methods in health technology, assessment
69. Randomised trial of oral aspirin for chronic venous leg ulcers
70. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study
71. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
72. Effects of antioxidants on the occurrence of pre-eclampsia in women at increased risk: A randomised trial
73. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial
74. Confidence intervals for the number needed to treat